Gan to kagaku ryoho. Cancer & chemotherapy
-
Gan To Kagaku Ryoho · May 2001
[Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
From June 1997 through December 1999, we treated twenty-two metastatic breast cancer patients with Docetaxel (60 mg/m2 administered intravenously every four weeks). All patients had received prior chemotherapy including anthracycline, and also another agent such as MMC-VDS, HDMTX-5-FU or CPT-11. One CR, 5 PR, and 4 Long NC were achieved. ⋯ Using the Kaplan Meier method, the median time to progression was 179 days, and the median survival time was 369 days. No serious adverse effects were observed. In this study Docetaxel seems to have shown significant activity, even for poor candidates, with intensive prior therapy.
-
Gan To Kagaku Ryoho · Feb 2001
Case Reports[Induction chemotherapy (cisplatin + vinorelbine) is found to be markedly effective for squamous cell lung carcinoma with sarcoidosis--a case report].
A sixty-one-year-old man was admitted to our hospital because of a right lung tumor shadow. He had been diagnosed as having sarcoidosis at the age of fifty-seven. He was newly diagnosed as having squamous cell carcinoma by trans bronchial biopsy. ⋯ Resected lung tissue showed the disappearance of cancer cells. Dissected mediastinal and hilar lymph nodes showed many sarcoid granulomas. Cisplatin combined with vinorelbine might be an effective chemotherapy for non-small cell lung carcinoma.
-
Since more than 50% of patients with cancer could no be cured by present standard therapy, new effective anticancer agents are needed in clinical level. In the evaluation of new anti-cancer agents by phase I study, there are several important and specific issues from scientific, medical, statistical, and ethical view points. Clinical safety data management is critically important in phase I study. This paper shows major parts of a report entitled "Guideline for phase I study on new anticancer agents", already published in JPs Pharmacol Ther 26: 441-454, 1998, with minor modification in order to answer these issues.
-
Gan To Kagaku Ryoho · Dec 2000
Review[New guidelines to evaluate the response to treatment "RECIST"].
Response evaluation criteria in solid tumors (RECIST) guidelines proposes the simplification of response evaluation through the use of unidimensional measurements and the sum of the longest diameters for all target lesions. Data from collaborative studies, including more than 4,600 patients assessed for tumor response, support the simplification of response evaluation through the use of unidimensional measurements in stead of the conventional method using two measurements and the sum of the products. In this criteria, PR is at least a 30% decrease and PD is at least a 20% increase in the sum of the longest diameter of target lesions. ⋯ But, in this criteria, there are some problems in Japanese studies. One of them is that we cannot use the endoscopic findings for the evaluation of gastric cancer except for validation purposes, and one is that long NC (long SD) on breast cancer does not exist in this response criteria. We had discussed these problems at the 38th meeting of Japan Society of Clinical Oncology.
-
There are no guidelines for dose escalation methods of combination chemotherapy. Thus, in order to evaluate this method, we selected 30 reports on two drug combination chemotherapies without support by BMT, that were published in the Journal of Clinical Oncology from 1997 to 1999. The present report describes the starting dose, patient number at each dose level, or dose escalation method in these 30 papers.